Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 18,757 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase I Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

NCT04130516
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
Drug · Biological
Lead sponsor
Linnaeus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 13, 2026, 5:33 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

NCT01938833
View directory record Official record
Conditions
HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Romidepsin, Abraxane
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Nov 13, 2026, 5:33 PM EST
Suspended Phase 1 Interventional

TR1801-ADC in Patients With Tumors That Express c-Met

NCT03859752
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
TR1801-ADC
Biological
Lead sponsor
Open Innovation Partners, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Chikungunya Virus Vaccine Trial in Healthy Adults

NCT01489358
View directory record Official record
Conditions
Viral Vaccines, Chikungunya Fever, Chikungunya Virus Infection
Interventions
VRC-CHKVLP059-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

NCT06698926
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-CLS-616, Placebo, Itraconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1 Interventional

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

NCT00136578
View directory record Official record
Conditions
Solid Tumours
Interventions
SB-715992, carboplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1 Interventional

Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors

NCT00006485
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, irinotecan hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of PRA023 in Healthy Volunteers

NCT04676178
View directory record Official record
Conditions
Healthy
Interventions
PRA023, Placebo
Drug · Other
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Nov 13, 2026, 5:33 PM EST
Terminated No phase listed Observational

Exploring The Role Of Palliative Care In Phase 1 Enrolled Pediatric Oncology Patients

NCT05412563
View directory record Official record
Conditions
Quality of Life
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
31 participants
Timeline
2022 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Nov 13, 2026, 5:33 PM EST
Recruiting Phase 1Phase 2 Interventional

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

NCT05351593
View directory record Official record
Conditions
CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Interventions
Tafasitamab, Lenalidomide
Drug
Lead sponsor
James Rubenstein
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1Phase 2 Interventional Results available

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02509052
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Leflunomide, Pharmacological Study
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

NCT05554926
View directory record Official record
Conditions
Marijuana Abuse
Interventions
AEF0117
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors

NCT00003478
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
conventional surgery, iodine I 131 monoclonal antibody 81C6, radiation therapy
Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

NCT06793943
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zasocitinib, COC, Metformin, Digoxin, Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1Phase 2 Interventional

Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

NCT00139243
View directory record Official record
Conditions
Squamous Cell Carcinoma, Carcinoma of Head and/or Neck
Interventions
Taxotere, Cisplatin, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Nov 13, 2026, 5:33 PM EST
Recruiting Phase 1 Interventional

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

NCT06874335
View directory record Official record
Conditions
Solid Tumor
Interventions
BHV-1530, Cemiplimab
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Newport Beach, California • Denver, Colorado • Lake Mary, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 13, 2026, 5:33 PM EST
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
View directory record Official record
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Nov 13, 2026, 5:33 PM EST
Not listed Phase 1Phase 2 Interventional

Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer

NCT00004063
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interferon alfa, cisplatin, gemcitabine hydrochloride, hyperthermia treatment
Biological · Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Nov 13, 2026, 5:33 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

NCT02696993
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Cognitive Assessment, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Biological · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population

NCT01877421
View directory record Official record
Conditions
Plaque, Gingivitis
Interventions
2 mg KSL-W, 4 mg KSL-W, 6 mg KSL-W, 10 mg KSL-W, 20 mg KSL-W, 30 mg KSL-W, 50 mg KSL-W, 75 mg KSL-W, 100 mg KSL-W, Placebo
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 64 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Nov 13, 2026, 5:33 PM EST
Terminated No phase listed Observational

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00008216
View directory record Official record
Conditions
Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Peripheral Blood Stem Cell Transplantation
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1Phase 2 Interventional Results available

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

NCT00766116
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
5-Azacitidine, Gemtuzumab ozogamicin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
3
States / cities
La Jolla, California • Stanford, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

NCT00402116
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
Interventions
enzastaurin, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Nov 13, 2026, 5:33 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC

NCT00746733
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lisdexamfetamine Dimesylate, Adderall XR (mixed salts amphetamine)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Nov 13, 2026, 5:33 PM EST